1
Eric First, M.D.
Eric R First: Botulinum toxin therapy for skin disorders. Allergan, Hal Gibson, Debra Condino, November 1, 2011: US08048423 (9 worldwide citation)

Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.


2
Eric First, M.D.
Eric R First: Stretch mark treatment. Allergan, Claude L Nassif, Stephen Donovan, Martin Voet, September 30, 2008: US07429386 (7 worldwide citation)

Methods for treating stretch marks by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a stretch mark.


3
Eric First, M.D.
Eric R First: Methods and compositions for treating eye disorders. Allergan, Claude L Hassif, Stephen Donovan, Martin A Voet, May 22, 2007: US07220422 (7 worldwide citation)

The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivi ...


4
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, BioTechnology Law Group, Daniel M Chambers, November 9, 2010: US07829674 (4 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


5
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lowrie Lando & Anastasi, October 28, 2008: US07442775 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


6
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Williams: Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08025877 (2 worldwide citation)

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


7
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08026342 (1 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


8
Eric First, M.D.
Eric First: Botulinum toxin therapy for skin disorders. Allergan, Brigitte C Phan, Ted Chan, Debra Condino, October 28, 2014: US08871224

Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.


9
Eric First, M.D.
Eric R First: Pressure sore treatment. Allergan, Brigitte C Phan, Ted Chan, Debra Condino, October 21, 2014: US08865177

Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.


10
Tarran Jones
Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. MedImmune, Mueting Raasch & Gebhardt P A, March 4, 2014: US08664363

Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutation ...